AbbVie reports SAPPHIRE-I HCV results

AbbVie (ABBV) is out with data from SAPPHIRE-I (that's the first of six 3D Phase 3 GT1 HCV trials).

SVR12 rates: 95% in GT1a and 98% in GT1b.

Regulatory submissions expected in Q2 of next year. (PR)

Worth watching on the news: Enanta (ENTA), which discovered one of the regimen's components (ABT-450) as part of an ongoing collaboration with ABBV.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs